Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 2Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 2Thyroid Diseases 1Paget Disease, Extramammary 1Neuroma, Acoustic 1Glioma 1Adenolymphoma 1

Interventions

Temozolomide 73Bevacizumab 58Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × Fluorescein × Clear all
NCT02691923 2025-08-03

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
30 enrolled
CNS

Brain Neoplasms, Glioma

NCT04597801 2022-11-10

INVIVO

Technical University of Munich

Phase 2 Completed
210 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡